Article | March 4, 2024

Demand More From Your ÄKTA Oligosynt™ Synthesizer

Source: Cytiva
Scientist GettyImages-1027139762

The oligonucleotide therapeutics market is expanding, characterized by a diverse pipeline. With over 2000 oligo therapeutics in development and 20 commercialized oligonucleotide drugs on the market, the potential of these highly specific sequences is being realized and is expected to continue growing.

In an oligo synthesizer, having the ability to optimize synthesis parameters and conditions for each cycle is crucial. Only through meticulous process optimization can both high quality and cost efficiency be achieved to produce an oligonucleotide at scale. Speed and efficiency in process development and scale-up hinge on having the expertise and experience to optimize synthesis processes along with comprehensive support for the entire workflow process. When you choose a system from Cytiva for your oligonucleotide workflow, you gain access to their network of oligonucleotide product specialists, scientists, and support associates. Gain insight into how you can fast-track your molecule's development with verified synthesizers, columns, and scientific support and expertise.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development